Avodart contains the following excipients: Capsule: Monoglyceride of caprylic/capric acid, butylated hydroxytoluene. Capsule Shell: Gelatin, glycerol, titanium dioxide (E171, Cl 77891), yellow iron oxide (E172, Cl 77492), medium chain triglycerides (MCT) and lecithin as lubricants.
Pharmacotherapeutic Group: Inhibitor of 5α-reductase. ATC Code: G04C B02.
Pharmacology: Pharmacodynamics: Dutasteride is a dual 5α-reductase inhibitors. It inhibits both types 1 and 2, 5α-reductase isoenzymes, which are responsible for the conversion of testosterone to dihydrotestosterone (DHT). Dihydrotestosterone is the androgen primarily responsible for hyperplasia of glandular prostatic tissue.
Effects on DHT/Testosterone: The maximum effect of daily doses of Avodart on the reduction on DHT is dose-dependent and is observed within 1-2 weeks. After 1 week and 2 weeks of daily dosing of Avodart 0.5 mg, median serum DHT concentrations were reduced by 85% and 90%, respectively.
In benign prostatic hyperplasia (BPH) patients treated with dutasteride 0.5 mg daily, the median decrease in DHT was 94% at 1 year and 93% at 2 years, and the median increase in serum testosterone was 19% at both 1 and 2 years. This is an expected consequence of 5α-reductase inhibition and did not result in any known adverse events.
Clinical Studies: Avodart Monotherapy for BPH: Dutasteride 0.5 mg/day or placebo was evaluated in 4325 male subjects with enlarged prostates (>30 cc) in 3 primary efficacy 2-year multicenter, placebo-controlled, double-blind studies.
In men with BPH, Avodart treats and prevents disease progression by reducing the risk of both acute urinary retention (AUR) and the need for surgical intervention (SI) and by providing statistically significant improvement of lower urinary tract symptoms (LUTS), maximum urinary flow rate (Qmax) and prostate volume relative to placebo. These improvements in LUTS, Qmax and prostate volume were seen through to 24 months, and LUTS and Qmax continued to improve for a further 2 years in open-label extension studies. In addition, reductions in prostate volume were sustained for a further 2 years in open-label extension studies.
Avodart and Tamsulosin Combination Therapy for BPH: Avodart 0.5 mg/day, tamsulosin 0.4 mg/day or the combination of Avodart 0.5 mg + tamsulosin 0.4 mg was evaluated in 4844 male subjects with enlarged prostates (≥30 cc) in a multicenter, double-blind, parallel group study over 4 years. The primary efficacy endpoint at 2 years of treatment was the level of improvement from baseline in the international prostate symptom score (IPSS).
After 2 years of treatment, combination therapy showed a statistically significant adjusted mean improvement in symptom scores from baseline of -6.2 units. The adjusted mean improvements in symptom scores observed with the individual therapies were -4.9 units for Avodart and -4.3 units for tamsulosin. The adjusted mean improvement in flow rate from baseline was 2.4 mL/sec for the combination, 1.9 mL/sec for Avodart and 0.9 mL/sec for tamsulosin. The adjusted mean improvement in BPH impact index (BII) from baseline was -2.1 units for the combination, -1.7 for Avodart and -1.5 for tamsulosin.
The reduction in total prostate volume and transition zone volume after 2 years of treatment was statistically significant for combination therapy compared to tamsulosin monotherapy alone.
The primary efficacy endpoint at 4 years of treatment was time to 1st event of AUR or BPH-related surgery. After 4 years of treatment, combination therapy statistically significantly reduced the risk of AUR or BPH-related surgery [65.8% reduction in risk p<0.001 (95% CI 54.7-74.1%)] compared to tamsulosin monotherapy. The incidence of AUR or BPH-related surgery by year 4 was 4.2% for combination therapy and 11.9% for tamsulosin (p<0.001). Compared to Avodart monotherapy, combination therapy reduced the risk of AUR or BPH-related surgery by 19.6%; the difference between treatment groups was not significant [p=0.18 (95% CI -10.9-41.7%)]. The incidence of AUR or BPH-related surgery by year 4 was 4.2% for combination therapy and 5.2% for Avodart.
Clinical progression was defined as a composite of worsening symptoms, IPSS, and BPH-related events of AUR, incontinence, urinary tract infection, and renal insufficiency. Combination therapy was associated with a statistically significantly lower rate of clinical progression compared with tamsulosin [p<0.001, 44.1% risk reduction (95% CI: 33.6-53%)] after 4 years. The rates of clinical progression for combination therapy, tamsulosin and Avodart were: 12.6, 21.5 and 17.8%, respectively.
The statistically significant adjusted mean improvement in symptom scores (IPSS) from baseline was maintained from years 2-4. At 4 years, the adjusted mean improvements in symptom scores observed were -6.3 units for combination therapy, -5.3 units for Avodart monotherapy and -3.8 units for tamsulosin monotherapy.
After 4 years of treatment, the adjusted mean improvement in flow rate (Qmax) from baseline was 2.4 mL/sec for combination therapy, 2 mL/sec for Avodart monotherapy and 0.7 mL/sec for tamsulosin monotherapy. Compared with tamsulosin, the adjusted mean improvement from baseline in Qmax was statistically significantly greater with combination therapy at each 6-month assessment from months 6-48 (p<0.001). Compared with Avodart, the adjusted mean improvement from baseline in Qmax was not statistically significantly different than with combination therapy (p=0.05 at month 48).
Combination therapy was significantly superior (p<0.001) to tamsulosin monotherapy and to Avodart monotherapy for the improvement in health outcome parameters BII and BPH-related Health Status (BHS) at 4 years. The adjusted mean improvement in BII from baseline was -2.2 units for the combination, -1.8 for Avodart and -1.2 for tamsulosin. The adjusted mean improvement in BHS from baseline was -1.5 units for the combination, -1.3 for Avodart and -1.1 for tamsulosin.
The reduction in total prostate volume and transition zone volume after 4 years of treatment was statistically significant for combination therapy compared to tamsulosin monotherapy alone.
Cardiac Failure: In a 4-year comparison of Avodart co-administered with tamsulosin and dutasteride or tamsulosin monotherapy in men with BPH [combination of Avodart and tamsulosin (CombAT) study], the incidence of the composite term cardiac failure in the combination group (14/1610, 0.9%) was higher than in either monotherapy group: Avodart, 4/1623 (0.2%) and tamsulosin, 10/1611 (0.6%). The relative risk estimate for time to 1st cardiac failure event was 3.57 (95% CI 1.17, 10.8) for combination treatment compared to Avodart monotherapy and 1.36 (95% CI 0.61, 3.07) compared to tamsulosin monotherapy. No causal relationship between Avodart (alone or in combination with an α-blocker) and cardiac failure has been established (see Precautions).
In a 4-year comparison of placebo and Avodart in 8231 men aged 50-75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10 ng/mL (the REDUCE study), there was a higher incidence of the composite term cardiac failure in subjects taking Avodart (30/4105, 0.7%) versus placebo (16/4126, 0.4%) for a relative risk estimate for time to 1st cardiac failure event of 1.91 (95% CI 1.04, 3.5). In a post-hoc analysis of concomitant α-blocker use, there was a higher incidence of the composite term cardiac failure in subjects taking Avodart and an α-blocker concomitantly (12/1152, 1%), compared to subjects not taking Avodart and an α-blocker concomitantly: Avodart and no α-blocker (18/2953, 0.6%), placebo and an α-blocker (1/1399, <0.1%), placebo and no α-blocker (15/2727, 0.6%). No causal relationship between Avodart (alone or in combination with an α-blocker) and cardiac failure has been established (see Precautions).
Prostate Cancer and High Grade Tumours: In a 4-year comparison of placebo and Avodart in 8231 men aged 50-75, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10 ng/mL (the REDUCE study), 6706 subjects had prostate needle biopsy data available for analysis to determine Gleason Scores. There were 1517 subjects diagnosed with prostate cancer in the study. The majority of biopsy-detectable prostate cancers in both treatment groups were diagnosed as low grade (Gleason 5-6). There was no difference in the incidence of Gleason 7-10 cancers (p=0.81).
There was a higher incidence of Gleason 8-10 prostate cancers in the Avodart group (n=29, 0.9%) compared to the placebo group (n=19, 0.6%) (p=0.15). In years 1-2, the number of subjects with Gleason 8-10 cancers was similar in the Avodart group (n=17, 0.5%) and the placebo group (n=18, 0.5%). In years 3-4, more Gleason 8-10 cancers were diagnosed in the Avodart group (n=12, 0.5%) compared with the placebo group (n=1, <0.1%) (p=0.0035). There are no data available on the effect of Avodart beyond 4 years in men at risk of prostate cancer. The percentage of subjects diagnosed with Gleason 8-10 cancers was consistent across study time periods (years 1-2 and 3-4) in the Avodart group (0.5% in each time period), while in the placebo group, the percentage of subjects diagnosed with Gleason 8-10 cancers was lower during years 3-4 than in years 1-2 (<0.1 vs 0.5%, respectively). In a 4-year BPH study (CombAT) where there were no protocol-mandated biopsies and all diagnoses of prostate cancer were based on for-cause biopsies, the rates of Gleason 8-10 cancer were (n=8, 0.5%) for Avodart, (n=11, 0.7%) for tamsulosin and (n=5, 0.3%) for combination therapy (see Precautions).
Effects on Prostate-Specific Antigen (PSA) and Prostate Cancer Detection: In a 4-year comparison of placebo and dutasteride in 8231 men 50-75 years, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10 ng/mL (the REDUCE study), Avodart treatment caused a decrease in mean serum PSA by approximately 50% after 6 months of treatment with a large variability (standard deviation of 30%) among patients. The PSA suppression observed at 6 months was similar in men who did or who did not develop biopsy-detectable prostate cancer during the study (see Precautions).
Incidence of Breast Cancer: In BPH monotherapy clinical trials, providing 3374 patient years of exposure to Avodart, there were 2 cases of breast cancer reported in Avodart-treated patients, one after 10 weeks and one after 11 months of treatment, and 1 case in a patient who received placebo. In subsequent clinical trials in BPH and 8231 men 50-75 years, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10 ng/mL providing 17,489 patient years exposure to Avodart and 5027 patient years exposure to Avodart and tamsulosin combination, there were no additional cases in any of the treatment groups. The relationship between long-term use of dutasteride and male breast cancer is unknown.
Pharmacokinetics: Absorption: Dutasteride is administered orally in solution as a soft gelatin capsule. Following administration of a single 0.5 mg dose, peak serum concentrations of dutasteride occur within 1-3 hrs.
Absolute bioavailability in man is approximately 60% relative to a 2-hr IV infusion. The bioavailability of dutasteride is not affected by food.
Distribution: Pharmacokinetic data following single and repeat oral doses show that dutasteride has a large volume of distribution (300-500 L). Dutasteride is highly bound to plasma proteins (>99.5%).
Following daily dosing, dutasteride serum concentrations achieve 65% of steady-state concentration after 1 month and approximately 90% after 3 months. Steady-state serum concentrations (Css) of approximately 40 ng/mL are achieved after 6 months of dosing 0.5 mg once daily. Similarly to serum, dutasteride concentrations in semen achieved steady-state at 6 months. After 52 weeks of therapy, semen dutasteride concentrations averaged 3.4 ng/mL (range 0.4-14 ng/mL). Dutasteride partitioning from serum into semen averaged 11.5%.
Biotransformation: In vitro, dutasteride is metabolized by the human cytochrome P-450 isoenzyme CYP3A4 to 2 minor monohydroxylated metabolites, but it is not metabolized by CYP1A2, CY2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6 or CYP2D6.
In human serum, following dosing to steady-state, unchanged dutasteride, 3 major metabolites (4'-hydroxydutasteride, 1,2-dihydrodutasteride and 6-hydroxydutasteride) and 2 minor metabolites (6,4'-dihydroxydutasteride and 15-hydroxydutasteride), as assessed by mass spectrometric response, have been detected. The 5 human serum metabolites of dutasteride have been detected in rat serum, however, the stereochemistry of the hydroxyl additions at the 6 and 15 positions in the human and rat metabolites is not known.
Elimination: Dutasteride is extensively metabolized. Following oral dosing of dutasteride 0.5 mg/day to steady-state in humans, 1-15.4% (mean of 5.4%) of the administered dose is excreted as dutasteride in the faeces. The remainder is excreted in the faeces as 4 major metabolites comprising 39, 21, 7 and 7% each of drug-related material and 6 minor metabolites (<5% each).
Only trace amounts of unchanged dutasteride (<0.1% of the dose) are detected in human urine.
At therapeutic concentrations, the terminal half-life (t½) of dutasteride is 3-5 weeks.
Serum concentrations remain detectable (>0.1 ng/mL) for up to 4-6 months after discontinuation of treatment.
Linearity/Non-Linearity: Dutasteride pharmacokinetics can be described as 1st order absorption process and 2 parallel elimination pathways, 1 saturable (concentration-dependent) and 1 non-saturable (concentration-independent).
At low serum concentrations (<3 ng/mL), dutasteride is cleared rapidly by both the concentration-dependent and concentration-independent elimination pathways. Single doses of ≤5 mg showed evidence of rapid clearance and a short half-life of 3-9 days.
At serum concentrations >3 ng/mL, dutasteride is cleared slowly (0.35-0.58 L/hr) primarily by linear, non-saturable elimination with terminal half-life of 3-5 weeks. At therapeutic concentrations, following repeat dosing of 0.5 mg/day, the slower clearance dominates and the total clearance is linear and concentration-independent.
Elderly: Dutasteride pharmacokinetics and pharmacodynamics were evaluated in 36 healthy male subjects 24-87 years following administration of a single 5-mg dose of dutasteride. Exposure of dutasteride, represented by AUC and Cmax values, was not statistically different when comparing age groups. Half-life was not statistically different when comparing the 50- to 69-year old group to the >70-year old group, which encompasses the age of most men with BPH. No differences in drug effect as measured by DHT reduction were observed between age groups. Results indicated that no dutasteride dose-adjustment based on age is necessary.
Renal Impairment: The effect of renal impairment on dutasteride pharmacokinetics has not been studied. However, <0.1% of a steady-state dutasteride 0.5-mg dose is recovered in human urine, so no adjustment in dosage is anticipated for patients with renal impairment.
Hepatic Impairment: The effect on the pharmacokinetics of dutasteride in hepatic impairment has not been studied (see Precautions).
Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).
Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH.
Avodart can be administered alone or in combination with the α-blocker tamsulosin 0.4 mg (see Pharmacology under Actions and Adverse Reactions).
Avodart may be taken with or without food. The capsules should be swallowed whole and not chewed or opened, as contact with the capsule contents may result in irritation of the oropharyngeal mucosa.
Adult Males (Including Elderly): Recommended Dose: 1 capsule (0.5 mg) taken orally once daily.
Although an improvement may be observed at an early stage, it can take up to 6 months before a response to the treatment can be achieved.
Renal Impairment: The effect of renal impairment on dutasteride pharmacokinetics has not been studied. No adjustment in dosage is anticipated for patients with renal impairment (see Pharmacology: Pharmacokinetics under Actions).
Hepatic Impairment: The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied so caution should be used in patients with mild o moderate hepatic impairment (see Pharmacology: Pharmacokinetics under Actions and Precautions). In patient with severe hepatic impairment, the use of dutasteride is contraindicated.
Administration: Avodart should be swallowed whole and may be taken with or without food.
In volunteer studies, single doses of dutasteride up to 40 mg/day (80 times the therapeutic dose) for 7 days have been administered without significant safety concerns. In clinical studies, doses of 5 mg daily have been administered to patients for 6 months with no additional adverse effects to those seen at therapeutic doses of 0.5 mg.
There is no specific antidote for dutasteride, therefore, in cases of suspected overdosage, symptomatic and supportive treatment should be given as appropriate.
Hypersensitivity to dutasteride, other 5α-reductase inhibitors, or any component of Avodart.
Use in pregnancy and children: Dutasteride is contraindicated for use by women and children. Dutasteride has not been studied in women because preclinical data suggests that the suppression of circulating levels of dihydrotestosterone may inhibit the development of the external genital organs in a male foetus carried by a woman exposed to dutasteride.
Dutasteride is absorbed through the skin, therefore women and children must avoid contact with leaking capsules. If contact is made with leaking capsules, the contact area should be washed immediately with soap and water (see Contraindications).
The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolized and has a t½ of 3-5 weeks, caution should be used in the administration of dutasteride to patients with liver disease (see Pharmacology: Pharmacokinetics under Actions and Dosage & Administration).
Combination Therapy with Tamsulosin and Cardiac Failure: In two 4-year clinical studies, the incidence of cardiac failure (a composite term of reported events, primarily cardiac failure and congestive cardiac failure) was higher among subjects taking the combination of Avodart and an α-blocker, primarily tamsulosin, than it was among subjects not taking the combination. In these 2 trials, the incidence of cardiac failure was low (≤1%) and variable between the studies. No imbalance was observed in the incidence of cardiovascular adverse events overall in either trial. No causal relationship between Avodart (alone or in combination with an α-blocker) and cardiac failure has been established (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Effects on Prostate-Specific Antigen (PSA) and Prostate Cancer Detection: Digital rectal examination, as well as other evaluations for prostate cancer, should be performed on patients prior to initiating therapy with dutasteride and periodically thereafter.
Serum PSA concentration is an important component of the screening process to detect prostate cancer. Avodart causes a decrease in mean serum PSA levels by approximately 50% after 6 months of treatment.
Patients receiving Avodart should have a new PSA baseline established after 6 months of treatment with Avodart. It is recommended to monitor PSA values regularly thereafter. Any confirmed increase from lowest PSA level while on Avodart may signal the presence of prostate cancer (particularly high grade cancer) or of noncompliance to therapy with Avodart and should be carefully evaluated, even if those values are still within the normal range for men not taking a 5α-reductase inhibitor (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions). In the interpretation of a PSA value for a patient taking Avodart, previous PSA values should be sought for comparison.
Treatment with Avodart does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Total serum PSA levels return to baseline within 6 months of discontinuing treatment.
The ratio of free to total PSA remains constant even under the influence of Avodart. If clinicians elect to use percent-free PSA as an aid in the detection of prostate cancer in men undergoing dutasteride therapy, no adjustment to its value is necessary.
Increased Risk of High-Grade Prostate Cancer: In a 4-year study of over 8000 men 50-75 years, with a prior negative biopsy for prostate cancer and baseline PSA between 2.5 ng/mL and 10 ng/mL (the REDUCE study), 1517 men were diagnosed with prostate cancer. There was a higher incidence of Gleason 8-10 prostate cancers in the Avodart group (n=29, 0.9%) compared to the placebo group (n=19, 0.6%). There was no increased incidence in Gleason 5-6 or 7-10 prostate cancers. No causal relationship between Avodart and high-grade prostate cancer has been established. The clinical significance of the numerical imbalance is unknown. Men taking Avodart should be regularly evaluated for prostate cancer risk including PSA testing (see Pharmacology: Pharmacodynamics under Clinical Studies under Actions).
5α-reductase inhibitors may increase the risk of development of high-grade prostate cancer. Whether the effect of 5α-reductase inhibitors to reduce prostate volume, or study-related factors, impacted the results of these studies has not been established.
Breast Cancer in Men: Breast cancer has been reported in men taking dutasteride in clinical trials (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions) and during the post-marketing period. Prescribers should instruct their patient to promptly report any changes in their breast tissue such as lumps or nipple discharge. It is not clear if there is a casual relationship between the occurence of male breast cancer and long term use of dutasteride.
Effects on the Ability to Drive or Operate Machinery: Based on the pharmacokinetic and pharmacodynamic properties of dutasteride, treatment with dutasteride would not be expected to interfere with the ability to drive or operate machinery.
Impairment of Fertility: The effects of dutasteride 0.5 mg/day on semen characteristics were evaluated in normal volunteers 18-52 years (n=27 dutasteride, n=23 placebo) throughout 52 weeks of treatment and 24 weeks of post-treatment follow-up. At 52 weeks, the mean percent reduction from baseline in total sperm count, semen volume and sperm motility were 23, 26 and 18%, respectively, in the dutasteride group when adjusted for changes from baseline in the placebo group. Sperm concentration and sperm morphology were unaffected. After 24 weeks of follow-up, the mean percent change in total sperm count in the dutasteride group remained 23% lower than baseline. While mean values for all semen parameters at all time points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), 2 subjects in the dutasteride group had decreases in sperm count of >90% from baseline at 52 weeks, with partial recovery at the 24-week follow-up. The clinical significance of dutasteride's effect on semen characteristics for an individual patient's fertility is not known.
Use in lactation: It is not known whether dutasteride is excreted in breast milk.
Use in pregnancy: Dutasteride is contraindicated for use by women. Dutasteride has not been studied in women because preclinical data suggests that the suppression of circulating levels of dihydrotestosterone may inhibit the development of the external genital organs in a male foetus carried by a woman exposed to dutasteride.
Use in lactation: It is not known whether dutasteride is excreted in breast milk.
Clinical Trial Data: Avodart Monotherapy for BPH: The following investigator-judged drug-related adverse events (with incidence ≥1%) have been reported more commonly in the 3 phase III placebo-controlled studies on Avodart treatment compared to placebo (see Table 1).
Click on icon to see table/diagram/image
No change to the adverse event profile was apparent over a further 2 years in open-label extension studies.
Avodart and Tamsulosin Combination Therapy for BPH: The following investigator-judged drug-related adverse events (with a cumulative incidence of ≥1%) have been reported in the CombAT study, a comparison of Avodart 0.5 mg and tamsulosin 0.4 mg once daily for 4 years in combination or as monotherapy. (See Table 2.)
Click on icon to see table/diagram/image
Post-Marketing Data: Adverse drug reactions are listed as follows by system organ class and frequency. Frequencies are defined as: Very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000) and very rare (<1/10,000) including isolated reports. Frequency categories determined from post-marketing data refer to reporting rate rather than true frequency.
Immune System Disorders: Very Rare: Allergic reactions including rash, pruritus, urticaria, localized oedema and angioedema.
Psychiatric Disorders: Very Rare: Depressed mood.
Skin and Subcutaneous Tissue Disorders: Rare: Alopecia (primarily body hair loss), hypertrichosis.
Reproductive System and Breast Disorder: Very Rare: Testicular pain and testicular swelling.
In vitro drug metabolism studies show that dutasteride is metabolised by human cytochrome P450 isoenzyme 3A4 (CYP3A4). Therefore, blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4.
Phase II data showed a decrease in clearance of dutasteride when co-administered with the CYP3A4 inhibitors verapamil (37%) and diltiazem (44%). In contrast, no decrease in clearance was seen when amlodipine, another calcium channel antagonist, was co-administered with dutasteride. A decrease in clearance and subsequent increase in exposure to dutasteride, in the presence of CYP3A4 inhibitors, is unlikely to be clinically significant due to the wide margin of safety (up to 10 times the recommended dose has been given to patients for up to 6 months), therefore no dose adjustment is necessary.
In vitro, dutasteride is not metabolized by human cytochrome P-450 isoenzymes CYP1A2, CYP2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP2B6 and CYP2D6.
Dutasteride neither inhibits human CYP450 drug-metabolizing enzymes in vitro nor induces CYP450 isoenzymes CYP1A, CYP2B and CYP3A in rats and dogs in vivo.
In vitro studies demonstrate that dutasteride does not displace warfarin, acenocoumorol, phenprocoumon, diazepam or phenytoin from plasma protein, nor do these model compounds displace dutasteride. Compounds that have been tested for drug interactions in man include tamsulosin, terazosin, warfarin, digoxin and cholestyramine, and no clinically significant pharmacokinetic or pharmacodynamic interactions have been observed.
Although specific interaction studies were not performed with other compounds, approximately 90% of the subjects in large phase III studies receiving dutasteride were taking other medications concomitantly. No clinically significant adverse interactions were observed in clinical trials when dutasteride was co-administered with antihyperlipidemics, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic blocking agents, calcium channel blockers, corticosteroids, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), phosphodiesterase type V inhibitors and quinolone antibiotics
Instructions for Use/Handling: Dutasteride is absorbed through the skin therefore, women and children must avoid contact with leaking capsules (see Use in pregnancy under Contraindications). If contact is made with leaking capsules, the contact area should be washed immediately with soap and water.
G04CB02 - dutasteride ; Belongs to the class of testosterone-5-alpha reductase inhibitors. Used in the treatment of benign prostatic hypertrophy.
Sign Out
Click on icon to see table/diagram/image
Click on icon to see table/diagram/image
